GSK To Maintain Avandia Sales Rep Totals After Bristol Copromotion Ends
Executive Summary
GlaxoSmithKline will continue to support the anti-diabetic Avandia with 2000 sales reps after a copromotion agreement with Bristol-Myers Squibb ends Aug. 20
You may also be interested in...
GSK Avandamet Antidiabetic Combo Expected In Pharmacies In November
GlaxoSmithKline's Avandamet combination rosiglitazone/metformin product for diabetes is expected to be available in November, the company said after Oct. 10 FDA approval
GSK Avandamet Antidiabetic Combo Expected In Pharmacies In November
GlaxoSmithKline's Avandamet combination rosiglitazone/metformin product for diabetes is expected to be available in November, the company said after Oct. 10 FDA approval
From The Quarterly Conference Calls
Geneva Augmentin generic reserve: Geneva's generic amoxicillin/clavulanate earnings are being placed in a reserve in the event the company loses GlaxoSmithKline's appeal of the Augmentin patent lawsuit, Novartis CEO Daniel Vasella said July 22. "We will book sales, but we will not book the earnings out of this product but put them in a reserve," the exec said. "The additional exposure should we - against all odds - lose the appeal next year, would be an amount which we can digest, I would say, rather easily." GSK is appealing a May 22 ruling in Geneva's favor; a decision could come as early as January (1"The Pink Sheet" May 27, p. 20). Geneva launched amoxicillin generics in June...